← boardnext 2027-03next 2027-11-22
CGEN
Compugen Ltddistress 1/10 · well-funded / low risk$2.40-1%today-23% from 52w high
Oncology 1
Lead: Ovarian Cancer · est. market ~$8B (approx, global)
Revenue
$73M
Liquidity
$100M
Runway
—
Shares 1y
0%
Price & events
+12.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
+3.0%
1W
+18.8%
1M
-17.8%
3M
+14.8%
6M
+52.9%
1Y
+29.7%
2Y
-64.0%
5Y
-81.2%
All
Overview
- Market Cap
- $226.93M
- Volume
- 5.36K
- 52 Week Range
- $1.33 – $3.10
- Total Shares
- 94.55M
- Float Shares
- 92.42M
- Short %
- 2.96%
- % Held by Insiders
- 2.08%
- % Held by Institutions
- 15.42%
- RVOL
- 0.02x
- Beta
- 2.77
Pipeline stages · 3 programs
COM701, Normal Saline
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
COM503, Zimberelimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dose escalation: COM902 monotherapy, Cohort expansion: COM902 (RDFE) monotherapy, Cohort e
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 1/2 | COM701, Normal Saline | Ovarian Cancer, Ovarian Cancer Recurrent | — | recruiting |
| 2027-11-22 Estimated 50% readout ~2027-12-22 | Phase 1 | COM503, Zimberelimab | Neoplasm, Cancer, Malignant Tumors | — | recruiting |
| 2026-04-01 | Phase 1 | Dose escalation: COM902 monotherapy, Cohort expansion: COM902 (RDFE) monotherapy, Cohort e | Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC | 94 | completed |
Catalyst news & presentations · 1
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-21Leerink PartnersOutperform
- 2026-04-07Lake StreetBuy
- 2026-01-07HC Wainwright & Co.Buy
Competitors — Ovarian Cancer
- ABBVAbbVie Inc.$451.1B · D2
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- CORTCORCEPT THERAPEUTICS INC$10.0B · D0
- XNCRXencor Inc$1.4B · D4
- VSTMVerastem, Inc.$515M · D5
- ZNTLZentalis Pharmaceuticals, Inc.$334M · D5
- NXTCNextCure, Inc.$16M · D9
- IMNNImunon, Inc.$7M · D8
- GMABGENMAB A/S— · D1
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-21Compugen to Participate in BTIG Biotechnology Conference 2026 - marketscreener.com
- 2026-07-21Compugen to Hold 1x1 Meetings at July 28-29 BTIG Event - Stock Titan
- 2026-07-21Compugen to Participate in BTIG Biotechnology Conference 2026 - Moomoo
- 2026-07-20Compugen (CGEN) to Release Q2 Financial Results on August 3, 2026 - GuruFocus
- 2026-07-20Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 - Yahoo Finance
- 2026-07-20Compugen's Cancer Immunotherapy Update Is Set for Aug. 3 - Stock Titan
- 2026-07-20Compugen to release Q2 2026 results, host conference call - Bitget
- 2026-07-13Compugen (CGEN) SVP Levine exercises options and sells 1,875 shares under plan - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.